187 related articles for article (PubMed ID: 32650752)
1. Farnesoid X receptor as marker of osteotropism of breast cancers through its role in the osteomimetism of tumor cells.
Absil L; Journé F; Larsimont D; Body JJ; Tafforeau L; Nonclercq D
BMC Cancer; 2020 Jul; 20(1):640. PubMed ID: 32650752
[TBL] [Abstract][Full Text] [Related]
2. Association between farnesoid X receptor expression and cell proliferation in estrogen receptor-positive luminal-like breast cancer from postmenopausal patients.
Journe F; Durbecq V; Chaboteaux C; Rouas G; Laurent G; Nonclercq D; Sotiriou C; Body JJ; Larsimont D
Breast Cancer Res Treat; 2009 Jun; 115(3):523-35. PubMed ID: 18563553
[TBL] [Abstract][Full Text] [Related]
3. Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation.
Journe F; Laurent G; Chaboteaux C; Nonclercq D; Durbecq V; Larsimont D; Body JJ
Breast Cancer Res Treat; 2008 Jan; 107(1):49-61. PubMed ID: 17333335
[TBL] [Abstract][Full Text] [Related]
4. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers.
Chiu JH; Wen CS; Wang JY; Hsu CY; Tsai YF; Hung SC; Tseng LM; Shyr YM
J Transl Med; 2017 May; 15(1):97. PubMed ID: 28472954
[TBL] [Abstract][Full Text] [Related]
5. Role of farnesoid X receptor (FXR) in the process of differentiation of bone marrow stromal cells into osteoblasts.
Id Boufker H; Lagneaux L; Fayyad-Kazan H; Badran B; Najar M; Wiedig M; Ghanem G; Laurent G; Body JJ; Journé F
Bone; 2011 Dec; 49(6):1219-31. PubMed ID: 21893226
[TBL] [Abstract][Full Text] [Related]
6. High Farnesoid X Receptor (FXR) expression is a strong and independent prognosticator in invasive breast carcinoma.
Giaginis C; Karandrea D; Alexandrou P; Giannopoulou I; Tsourouflis G; Troungos C; Danas E; Keramopoulos A; Patsouris E; Nakopoulou L; Theocharis S
Neoplasma; 2017; 64(4):633-639. PubMed ID: 28485172
[TBL] [Abstract][Full Text] [Related]
7. Activation of Farnesoid X Receptor impairs the tumor-promoting function of breast cancer-associated fibroblasts.
Barone I; Vircillo V; Giordano C; Gelsomino L; Győrffy B; Tarallo R; Rinaldi A; Bruno G; Caruso A; Romeo F; Bonofiglio D; Andò S; Catalano S
Cancer Lett; 2018 Nov; 437():89-99. PubMed ID: 30176263
[TBL] [Abstract][Full Text] [Related]
8. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis.
Cai D; Cao J; Li Z; Zheng X; Yao Y; Li W; Yuan Z
BMC Cancer; 2009 Apr; 9():102. PubMed ID: 19338666
[TBL] [Abstract][Full Text] [Related]
9. Lipids isolated from bone induce the migration of human breast cancer cells.
Silva J; Dasgupta S; Wang G; Krishnamurthy K; Ritter E; Bieberich E
J Lipid Res; 2006 Apr; 47(4):724-33. PubMed ID: 16439808
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of farnesoid X receptor controls esophageal cancer cell growth in vitro and in nude mouse xenografts.
Guan B; Li H; Yang Z; Hoque A; Xu X
Cancer; 2013 Apr; 119(7):1321-9. PubMed ID: 23280144
[TBL] [Abstract][Full Text] [Related]
11. Positive regulation of osteogenesis by bile acid through FXR.
Cho SW; An JH; Park H; Yang JY; Choi HJ; Kim SW; Park YJ; Kim SY; Yim M; Baek WY; Kim JE; Shin CS
J Bone Miner Res; 2013 Oct; 28(10):2109-21. PubMed ID: 23609136
[TBL] [Abstract][Full Text] [Related]
12. Monitoring metastatic behavior of human tumor cells in mice with species-specific polymerase chain reaction: elevated expression of angiogenesis and bone resorption stimulators by breast cancer in bone metastases.
van der Pluijm G; Sijmons B; Vloedgraven H; Deckers M; Papapoulos S; Löwik C
J Bone Miner Res; 2001 Jun; 16(6):1077-91. PubMed ID: 11393785
[TBL] [Abstract][Full Text] [Related]
13. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
Swales KE; Korbonits M; Carpenter R; Walsh DT; Warner TD; Bishop-Bailey D
Cancer Res; 2006 Oct; 66(20):10120-6. PubMed ID: 17047076
[TBL] [Abstract][Full Text] [Related]
14. Farnesoid X receptor inhibits proliferation of human colorectal cancer cells via the miR‑135A1/CCNG2 signaling pathway.
Qiao P; Li S; Zhang H; Yao L; Wang F
Oncol Rep; 2018 Oct; 40(4):2067-2078. PubMed ID: 30106441
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Predictive Immunohistochemical Marker Expression of Primary Breast Cancer and Paired Distant Metastasis using Surgical Material: A Practice-Based Study.
Kulka J; Székely B; Lukács LV; Kiss O; Tőkés AM; Vincze E; Turányi E; Fillinger J; Hanzély Z; Arató G; Szendrői M; Győrffy B; Szász AM
J Histochem Cytochem; 2016 Apr; 64(4):256-67. PubMed ID: 27029768
[TBL] [Abstract][Full Text] [Related]
16. PREX1 drives spontaneous bone dissemination of ER+ breast cancer cells.
Clements ME; Johnson RW
Oncogene; 2020 Feb; 39(6):1318-1334. PubMed ID: 31636389
[TBL] [Abstract][Full Text] [Related]
17. ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.
Bouchet M; Lainé A; Boyault C; Proponnet-Guerault M; Meugnier E; Bouazza L; Kan CWS; Geraci S; El-Moghrabi S; Hernandez-Vargas H; Benetollo C; Yoshiko Y; Duterque-Coquillaud M; Clézardin P; Marie JC; Bonnelye E
Cancer Res; 2020 Jul; 80(13):2914-2926. PubMed ID: 32366476
[TBL] [Abstract][Full Text] [Related]
18. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
19. Activated FXR Inhibits Leptin Signaling and Counteracts Tumor-promoting Activities of Cancer-Associated Fibroblasts in Breast Malignancy.
Giordano C; Barone I; Vircillo V; Panza S; Malivindi R; Gelsomino L; Pellegrino M; Rago V; Mauro L; Lanzino M; Panno ML; Bonofiglio D; Catalano S; Andò S
Sci Rep; 2016 Feb; 6():21782. PubMed ID: 26899873
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy.
Catalano S; Panza S; Malivindi R; Giordano C; Barone I; Bossi G; Lanzino M; Sirianni R; Mauro L; Sisci D; Bonofiglio D; Andò S
Int J Cancer; 2013 May; 132(10):2237-47. PubMed ID: 23124354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
